Labcorp Holdings Inc. (LH) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offer...
Labcorp Holdings Inc.'s revenue increased 7.2% year over year, from $13.01B to $13.95B.
Net income increased 17.5% over the same period, from $746.0M to $876.5M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 45% in total.
Total debt remained relatively stable at $5.08B.
The debt-to-equity ratio stands at 0.59, indicating a moderate leverage profile.
Operating cash flow grew 3.4% to $1.64B.
Labcorp Holdings Inc. maintains a moderate net profit margin of 6.3%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $3.28B+1.9% | $169.3M | $904.4M | $254.1M | $277.3M | $18.61B | $5.35B | $8.17B |
| Q4 FY2024 | $3.33B+1.4% | $143.4M | $896.3M | $216.5M | $777.2M | $18.38B | $5.33B | $8.05B |
| Q1 FY2025 | $3.35B+0.5% | $212.8M | $948.0M | $326.0M | $18.5M | $17.60B | $5.57B | $8.31B |
| Q2 FY2025 | $3.53B+5.4% | $237.9M | $1.05B | $394.5M | $620.6M | $18.06B | $5.08B | $8.47B |
| Q3 FY2025 | $3.56B+1.0% | $261.1M | $1.03B | $396.6M | $387.2M | $18.26B | $5.08B | $8.70B |
| Q4 FY2025 | $3.52B-1.3% | $164.7M | $993.2M | $267.6M | $614.2M | $18.39B | $5.08B | $8.62B |
| Q1 FY2026 | $3.54B+0.6% | $277.8M | $1.01B | $380.8M | $191.5M | $19.09B | $7.29B | $8.75B |
| Q2 FY2026 | $3.73B+5.5% | $298.7M | $1.11B | $451.6M | $445.5M | $18.53B | $6.82B | $8.62B |
Balance Sheet Summary (Q2 FY2026)
Labcorp Holdings Inc. (LH) Financial Statements & Revenue History
Labcorp Holdings Inc. (LH) is a US-listed stock operating in the Healthcare sector, specifically the Diagnostics & Research industry trading at $317.95 with a market capitalization of $26. This page provides 41 historical financial statements for Labcorp Holdings Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Labcorp Holdings Inc. reported revenue of $14.0 billion, representing 7.2% year-over-year growth. The net profit margin of 6.3% indicates moderate profitability. The debt-to-equity ratio of 0.59 reflects moderate leverage.
LH Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Labcorp Holdings Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether LH is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track LH's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Labcorp Holdings Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of LH's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use LH Financial Data
Investors use Labcorp Holdings Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare LH's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how LH's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View LH's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Labcorp Holdings Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.LH trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.